Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Commentary

Misplaced advocacy: What does better hepatitis C treatment really mean?

Mark Tyndall
CMAJ October 20, 2015 187 (15) 1111-1112; DOI: https://doi.org/10.1503/cmaj.150612
Mark Tyndall
BC Centre for Disease Control, Vancouver, BC
MD ScD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Well-placed Advocacy
    Bonnie R. Larson
    Posted on: 13 January 2016
  • Posted on: (13 January 2016)
    Page navigation anchor for Well-placed Advocacy
    Well-placed Advocacy
    • Bonnie R. Larson, Family Physician

    Dr. Tyndall has provided a thoughtful commentary on the current state of hepatitis C treatment, and is duly respectful of non-medical determinants of health, which are heavy influences on hepatitis C epidemiology. As a physician providing frontline care for patients infected with this disease, I would caution against presuming scarcity and approaching this problem with an either (treatment)-or (prevention) paradigm. We...

    Show More

    Dr. Tyndall has provided a thoughtful commentary on the current state of hepatitis C treatment, and is duly respectful of non-medical determinants of health, which are heavy influences on hepatitis C epidemiology. As a physician providing frontline care for patients infected with this disease, I would caution against presuming scarcity and approaching this problem with an either (treatment)-or (prevention) paradigm. We applied such a paradigm in the past with HIV and drug resistant tuberculosis, only to find that treatment is actually one very good weapon in the prevention arsenal.

    Although the author does advocate for resources to be spent "upstream" at the level of prevention and addiction treatment, he does not recognize that finding a way to treat ALL cases of hepatitis C would actually be part of a complete prevention and harm reduction strategy. We must avoid the trap of assuming that we are slaves to limited resources, and instead continually seek innovative ways to provide our patients the standard of care. And I, as a service provider to Canada's most vulnerable individuals (poor, homeless, indigenous, women and children suffering from abuse, mentally ill), am compelled to find ways to provide even better care than the standard, to my patients who are already at increased risk of suffering.

    Yes, the new HCV treatment regimens are expensive. Does that mean we should ration those treatments based on cost, or fight hard for a fairer price and good access for all? As a health equity professional, I am going to place my advocacy where it belongs: the latter.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (15)
CMAJ
Vol. 187, Issue 15
20 Oct 2015
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Misplaced advocacy: What does better hepatitis C treatment really mean?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Misplaced advocacy: What does better hepatitis C treatment really mean?
Mark Tyndall
CMAJ Oct 2015, 187 (15) 1111-1112; DOI: 10.1503/cmaj.150612

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Misplaced advocacy: What does better hepatitis C treatment really mean?
Mark Tyndall
CMAJ Oct 2015, 187 (15) 1111-1112; DOI: 10.1503/cmaj.150612
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • Well-placed advocacy
  • PubMed
  • Google Scholar

Cited By...

  • Well-placed advocacy
  • Google Scholar

More in this TOC Section

  • How can Canada’s health systems improve care for people with chronic obstructive pulmonary disease?
  • Minimally invasive procedures in gender-affirming care: the case for public funding across Canada
  • Time for Canada to align with global innovations in treatment for tuberculosis
Show more Commentary

Similar Articles

Collections

  • Topics
    • Drugs: gastrointestinal system
    • Hepatology
    • Prison medicine
    • Public health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire